EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

Tamir Shragai, Muhammad Ganayem, Yael C Cohen, Irit Avivi, Eyal Lebel, Noa Even-Gross Zohar, Natan Melamed, Moshe E Gatt

Annals of Hematology · 12.03.2026 · 105 (4)

DOI: 10.1007/s00277-026-06931-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 12.03.2026. Verfasst von Tamir Shragai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. tamirsh@tlvmc.gov.il. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Talquetamab, a CD3/GPRC5D T-cell engager approved for triple class exposed myeloma patients, inducing deep and durable responses. Very few cases of relapsed/refractory (R/R) light chain (AL) amyloidosis patients treated with talquetamab, were reported to date. We report six heavily pretreated R/R AL amyloidosis patients with severe end-organ damage (five with cardiac involvement), treated with talquetamab. Talquetamab induced rapid and deep responses: Five patients achieved complete response. (including MRD negativity in all three evaluable patients). At data cut-off, three patients were alive and relapse-free at 8, 15 and 24 months, and three patients died, after 1, 1.5 and 5 months since initiation of treatment. Five patients were not evaluable for organ response: (Three due to end-organ kidney disease, and two who died before organ response assessment). One patient achieved cardiac response. Two patients were referred to kidney transplantation after achieving CR. Cytokine release syndrome occurred in four patients, all grade 1–2, and immune effector cell associated neurotoxicity syndrome (ICANS) was reported in one patient (grade 2). Infections occurred in two patients (one grade 3, one grade 5). Congestive heart failure exacerbation occurred in two patients (grades 3 and 4). Our results support talquetamab as an effective therapy for RRAL patients, although larger-scale studies are needed to optimize earlier timing and patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisHumansFemaleMaleMiddle AgedAgedTreatment OutcomeImmunoglobulin Light ChainsAntibodies, Bispecific

Stichwörter der Autor:innen

Light-chain amyloidosisPlasma cell disordersRelapse/refractory amyloidosisT-cell engagers

Substanzen

Immunoglobulin Light ChainstalquetamabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. tamirsh@tlvmc.gov.il.
  • Gray Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. tamirsh@tlvmc.gov.il.
  • Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Gray Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.
  • Hadassah Medical School, Hebrew University, Jerusalem, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

Shragai, T., Ganayem, M., Cohen, Y. C., Avivi, I., Lebel, E., Even-Gross Zohar, N., Melamed, N., & Gatt, M. E. (2026). Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06931-3

Vancouver

Shragai T, Ganayem M, Cohen YC, Avivi I, Lebel E, Even-Gross Zohar N, et al. Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06931-3

BibTeX
@article{Shragai2026,
  author = {Shragai, Tamir and Ganayem, Muhammad and Cohen, Yael C and Avivi, Irit and Lebel, Eyal and Even-Gross Zohar, Noa and Melamed, Natan and Gatt, Moshe E},
  title = {Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {4},
  doi = {10.1007/s00277-026-06931-3}
}
Kostenlos starten →